Trial Profile
HbA1c goal attainment in patients with type 2 diabetes mellitus initiated on oral canagliflozin versus injectable glucagon-like peptide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Oct 2019
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Glucagon-like peptide-1
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Oct 2017 New trial record
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes